Tofranil

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more

Treatment

20 Active Studies for Tofranil

What is Tofranil

Imipramine

The Generic name of this drug

Treatment Summary

Imipramine is an antidepressant medication from the tricyclic antidepressant (TCA) family. It has a positive effect on mood for people with depression, but has little effect on those who are not depressed. Imipramine works by blocking serotonin and norepinephrine reuptake and by blocking certain receptors in the body. It has fewer sedative and anticholinergic effects than other TCAs, such as amitriptyline and clomipramine. Common uses of imipramine include treating depression and bedwetting in children, but it may also be used to treat chronic pain, panic

Tofranil

is the brand name

image of different drug pills on a surface

Tofranil Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tofranil

Imipramine

1959

103

Effectiveness

How Tofranil Affects Patients

Imipramine is an antidepressant medication that works by blocking the reuptake of serotonin and norepinephrine in the brain. This increases the levels of these neurotransmitters, which helps to improve depressive symptoms. Imipramine has also been shown to increase neurogenesis in the hippocampus, and reduce the downregulation of this neurogenesis caused by stress. It is also thought to cause a decrease in the number of beta-adrenergic receptors in the brain.

How Tofranil works in the body

Imipramine helps to treat depression by stopping the brain from taking back two important chemicals, norepinephrine and serotonin. These chemicals are responsible for stimulating the post-synaptic neuron and when they are slowed down, they stay in the brain longer and produce changes that help relieve the symptoms of depression.

When to interrupt dosage

The recommended dosage of Tofranil is contingent upon the diagnosed affliction, including Bedwetting, Bulimia Nervosa and Depression. The measure of dosage is also influenced by the mode of delivery (e.g. Tablet, sugar coated or Tablet, sugar coated - Oral) depicted in the following table.

Condition

Dosage

Administration

Nocturnal Enuresis (bedwetting)

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Neuropathic Pain

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Panic Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Bulimia Nervosa

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Depression

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Attention Deficit Hyperactivity Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated - Oral, Tablet, sugar coated, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Warnings

Tofranil Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Tofranil.

Common Tofranil Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.

Alfuzosin

Major

Imipramine may increase the hypotensive activities of Alfuzosin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Imipramine.

Amoxapine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.

Tofranil Toxicity & Overdose Risk

Imipramine can cause dry mouth, blurry vision, high body temperature, constipation, difficulty urinating, and drowsiness. It can also cause anorexia, nausea, vomiting, stomach discomfort, strange taste in the mouth, and a black tongue. Rarely, it can cause a decrease in white blood cells, platelets, and red blood cells. When taken by pregnant women, it may cause heart problems, restlessness, muscle spasms, seizures, and difficulty urinating in the baby. Taking imipramine with other drugs that increase serotonin levels can cause serotonin syndrome. The toxic dosage of imipram

image of a doctor in a lab doing drug, clinical research

Tofranil Novel Uses: Which Conditions Have a Clinical Trial Featuring Tofranil?

At present, 779 active trials are evaluating the potential of Tofranil to mitigate Attention Deficit Hyperactivity Disorder, Bulimia Nervosa and Depression.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

57 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Nocturnal Enuresis (bedwetting)

2 Actively Recruiting

Not Applicable

Depression

301 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Bulimia Nervosa

0 Actively Recruiting

Panic Disorder

13 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Tofranil Reviews: What are patients saying about Tofranil?

5

Patient Review

6/13/2016

Tofranil for Bedwetting

I gave this to my 8 year old grandson who wet the bed every night, and it worked perfectly. His dad was 5 years old when I used this on him, and it cleared up his problem in just three days.

5

Patient Review

11/18/2013

Tofranil for Problems with Bladder Control

I've been using this medication for a while now to treat my incontinence, and it's worked great! I haven't had any accidents since starting the Tofranil, and bedwetting is no longer an issue. I highly recommend this product.

5

Patient Review

11/6/2015

Tofranil for Panic Disorder

I've taken this medication for over 30 years now to prevent night terrors. My doctor and I have attempted to wean me off of it several times, but each time the night terrors come back. So, as long as it keeps working, I'll keep taking it. It's been a true blessing with no negative side effects.

4.7

Patient Review

2/9/2013

Tofranil for Attention Deficit Disorder with Hyperactivity

My grandson started this treatment for enuresis and ADHD when he was five years old. It worked great at first, but after six months we had to increase the dose to keep the same results. He's doing well now, but I wonder if a child can build up a tolerance to this medication over time.

4.3

Patient Review

3/6/2014

Tofranil for Depression

Tofranil saved my life. After trying and failing to take Zoloft and Lexapro, I started on Tofranil at a low dose of 10mg. Every two days, I increased the dosage by 10mg until I reached 150mg--all taken at night. At first, I experienced dry mouth and blurred vision; however, after just a few weeks, I felt so much better. My depression had lifted, my panic was manageable, and my anxiety was back to normal.

3.7

Patient Review

5/22/2012

Tofranil for Anxious

1

Patient Review

10/10/2016

Tofranil for Bedwetting

I would not recommend this medication to anyone. My son began taking it for bedwetting and very quickly started exhibiting signs of severe emotional distress, including self-harm and outbursts of violence. I contacted his doctor right away and had him taken off the medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tofranil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of drug is Tofranil?

"In chemistry, generally speaking, organic compounds are any chemical compounds that contain either carbon-hydrogen or carbon-carbon bonds. The reason for this is that carbon has the ability to catenate, or form chains with other carbon atoms. This results in there being millions of known organic compounds."

Answered by AI

What is Tofranil used to treat?

"This medication is typically used to treat depression, but it can also be used in conjunction with other therapies to treat nighttime bed-wetting in children. This medication may improve your mood, sleep, appetite, and energy level, and restore your interest in daily living."

Answered by AI

What does Tofranil do to the brain?

"It is believed that Tofranil elevates mood by increasing the levels of neurotransmitters in the brain."

Answered by AI

Does Tofranil help with anxiety?

"When other stimulants are not effective, Tofranil, a tricyclic antidepressant, may be prescribed. Tofranil can be effective in treating symptoms of ADHD in adults, as well as depression and anxiety that often accompany ADHD."

Answered by AI

Clinical Trials for Tofranil

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Recruiting
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Have you considered Tofranil clinical trials?

We made a collection of clinical trials featuring Tofranil, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Tofranil clinical trials?

We made a collection of clinical trials featuring Tofranil, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of Providence VA Medical Center, Providence, RI in Providence, United States.

Intermittent Theta-Burst Stimulation for ADHD

18 - 65
All Sexes
Providence, RI

Impaired inhibitory response manifests clinically as increased impulsivity, which leads to poorer affective, cognitive, social, and occupational functioning. Neuropsychiatric disorders prevalent among Veterans, such as Attention Deficit/Hyperactivity Disorder (ADHD), are associated with poor inhibitory control. The mainstay of clinical treatment for ADHD is psychostimulants, yet these medications have significant risks, including dependence and numerous side effects. Thus, novel and non-pharmacological therapeutic strategies are needed. Intermittent Theta Burst Stimulation, a newer form of transcranial magnetic stimulation, has emerged as a promising tool for modulating inhibitory neuronal circuits. This research proposal will investigate the feasibility and acceptability of iTBS on inhibitory control and impulsivity through a randomized controlled trial to inform clinical observations. The long-term goal is to improve impulsivity, social and occupational functioning, and enhance the quality of life for Veterans.

Waitlist Available
New This Month

Providence VA Medical Center, Providence, RI

Camila Souza A Cosmo, PhD

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Tofranil clinical trials?

We made a collection of clinical trials featuring Tofranil, we think they might fit your search criteria.
Go to Trials